Perrigo Company plc (NYSE:PRGO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its holdings in Perrigo Company plc (NYSE:PRGO - Free Report) by 3.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,277,428 shares of the company's stock after selling 215,851 shares during the quarter. Dimensional Fund Advisors LP owned approximately 4.63% of Perrigo worth $202,007,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PRGO. GAMMA Investing LLC acquired a new position in Perrigo during the 4th quarter worth approximately $30,000. Parkside Financial Bank & Trust grew its position in Perrigo by 1,694.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,041 shares of the company's stock valued at $34,000 after purchasing an additional 983 shares during the period. Hexagon Capital Partners LLC acquired a new position in Perrigo during the fourth quarter worth $37,000. Blue Trust Inc. lifted its stake in shares of Perrigo by 34.5% in the fourth quarter. Blue Trust Inc. now owns 1,556 shares of the company's stock valued at $50,000 after buying an additional 399 shares in the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Perrigo by 39.5% during the third quarter. Fifth Third Bancorp now owns 1,714 shares of the company's stock valued at $55,000 after buying an additional 485 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Stock Performance

Shares of NYSE:PRGO traded down $0.12 during midday trading on Thursday, reaching $30.10. The company had a trading volume of 1,551,998 shares, compared to its average volume of 1,773,189. The stock has a market cap of $4.10 billion, a P/E ratio of -430.14 and a beta of 0.63. The company's 50 day moving average price is $31.15 and its 200 day moving average price is $31.00. The company has a current ratio of 1.81, a quick ratio of 1.08 and a debt-to-equity ratio of 0.77. Perrigo Company plc has a 52-week low of $25.77 and a 52-week high of $40.28.

Perrigo (NYSE:PRGO - Get Free Report) last released its earnings results on Saturday, May 4th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. The firm had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a negative net margin of 0.17% and a positive return on equity of 6.96%. The company's quarterly revenue was down 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.45 earnings per share. As a group, sell-side analysts anticipate that Perrigo Company plc will post 2.57 EPS for the current fiscal year.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 18th. Stockholders of record on Friday, May 31st will be given a dividend of $0.276 per share. The ex-dividend date of this dividend is Friday, May 31st. This represents a $1.10 dividend on an annualized basis and a dividend yield of 3.67%. Perrigo's dividend payout ratio is presently -1,571.43%.

Insider Transactions at Perrigo

In other Perrigo news, EVP Alison Ives purchased 2,490 shares of the stock in a transaction dated Tuesday, March 5th. The shares were bought at an average price of $27.26 per share, with a total value of $67,877.40. Following the completion of the transaction, the executive vice president now directly owns 16,122 shares in the company, valued at approximately $439,485.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Alison Ives acquired 2,490 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The shares were acquired at an average price of $27.26 per share, with a total value of $67,877.40. Following the acquisition, the executive vice president now owns 16,122 shares of the company's stock, valued at approximately $439,485.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Willis bought 6,000 shares of Perrigo stock in a transaction on Thursday, February 29th. The shares were bought at an average cost of $25.87 per share, with a total value of $155,220.00. Following the acquisition, the executive vice president now directly owns 25,105 shares in the company, valued at $649,466.35. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 17,990 shares of company stock worth $475,227. 0.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Canaccord Genuity Group reiterated a "buy" rating and set a $42.00 price target on shares of Perrigo in a research note on Friday, April 12th. Piper Sandler raised their price objective on Perrigo from $35.00 to $39.00 and gave the company an "overweight" rating in a research note on Monday, April 8th. StockNews.com upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Perrigo from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Wednesday, February 28th.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.